Stoneridge Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stoneridge Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,545	Closed	-$693K	–	118
2024 Q4	$693K	Buy	10,545 +6,355	+152%	+$426K	0.25%	78
2024 Q3	$295K	Buy	+4,190	New	+$350K	0.11%	85
2023 Q1	–	Sell	-4,341	Closed	-$449K	–	101
2022 Q4	$449K	Buy	4,341 +1,399	+48%	+$131K	0.25%	71
2022 Q3	$249K	Sell	2,942 -6,388	-68%	-$569K	0.15%	88
2022 Q2	$773K	Hold	9,330	–	–	0.43%	60
2022 Q1	$719K	Buy	+9,330	New	+$781K	0.34%	72
2021 Q4	–	Sell	-4,241	Closed	-$328K	–	113
2021 Q3	$328K	Buy	4,241 +1,475	+53%	+$116K	0.16%	95
2021 Q2	$231K	Sell	2,766 -3,100	-53%	-$246K	0.11%	96
2021 Q1	$443K	Buy	+5,866	New	+$479K	0.23%	83
2020 Q4	–	Sell	-2,861	Closed	-$218K	–	109
2020 Q3	$218K	Buy	+2,861	New	+$289K	0.14%	100

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stoneridge Investment Partners's BMRN Position: Q1 2025 in Review

Stoneridge Investment Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 10,545 shares — an estimated $693K sold.

Stoneridge Investment Partners first reported a position in BMRN in Q3 2020 and held it in 10 quarters. The position peaked at $773K in Q2 2022. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Stoneridge Investment Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Stoneridge Investment Partners sold 10,545 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $693K.
Stoneridge Investment Partners first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 10 quarters.
Stoneridge Investment Partners's BioMarin Pharmaceuticals position peaked at $773K in Q2 2022.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Stoneridge Investment Partners's 13F filing for Q1 2025, filed 14 May 2025.